Sanofi (NASDAQ:SNY) finished Wednesday with an addition of $0.56 to close at $53.22, an upside of 1.06 percent. An average of 1,616,580 shares of common stock have been traded in the last five days. There was a gain of $1.73 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 1,370,050 shares traded, while the 50-day average volume stands at 1,222,712.
SNY stock has increased by 2.90% in the last month. The company shares reached their 1-month lowest point of $49.97 on 08/03/23. With the stock rallying to its 52-week high on 04/26/23, shares of the company touched a low of $36.91 and a high of $57.82 in 52 weeks. It has reached a new high 18 times so far this year and achieved 9.89% or $4.79 in price. In spite of this, the price is down -7.96% from the 52-week high.
Valuation Metrics
Sanofi (SNY) has a trailing price-to-earnings (P/E) ratio of 14.19. The stock’s beta is 0.56. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.60, the price-to-book (PB) ratio at 1.67.
The company has a payout ratio of 53.27%. The company’s most recent quarterly dividend payment was $1.3770 a share, representing a down of -23.36% from $1.7968 last year. Its latest decrease dividend $0.4198 reported on Tuesday May 30 2023.
Financial Health
The quick ratio of Sanofi for the three months ended June 29 was 0.80, and the current ratio was 1.20, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.23 and a total debt to equity ratio of 0.29 for the quarter ending June 29. Sanofi’s EBITDA margin for the year ending June 29 is 31.93%. Its gross profit as reported stood at $33.39 billion compared to revenue of $47.82 billion.
Earnings Surprise
For the three-month period that ended June 29, Sanofi had $418.88 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $9.38 billion in the quarter, while revenues were shrunk -47.1%. The analyst consensus anticipated Sanofi’s latest quarter earnings to come in at $1.55 per share, but it turned out to be $0.95, a -38.70% surprise. For the quarter, EBITDA amounted to $2.04 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Sanofi (SNY) price momentum. RSI 9-day as of the close on 09 August was 55.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 24.93%.
As of today, SNY’s price is $52.10 +3.36% or $1.73 from its 5-day moving average. SNY is currently trading +2.68% higher than its 20-day SMA and +10.60% higher than its 100-day SMA. However, the stock’s current price level is +1.35% above the SMA50 and +34.29% above the SMA200.
The stochastic %K and %D were 53.40% and 42.62%, respectively, and the average true range (ATR) was 0.91. With the 14-day stochastic at 65.00% and the average true range at 0.88, the RSI (14) stands at 53.11%. The stock has reached 0.32 on the 9-day MACD Oscillator while the 14-day reading was at -0.26.
Analyst Ratings
HSBC Securities launched coverage on Sanofi (NASDAQ: SNY) in its analyst report released on July 14, 2023. The firm assigned the stock a Buy rating. The consensus rating for Sanofi (SNY) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell SNY, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 4 analysts, while 12 others rate it as a “buy”.
What is SNY’s price target for the next 12 months?
Analysts predict a range of price targets between $49.66 and $75.47, with a median target of $62.00. Taking a look at these predictions, the average price target given by analysts for Sanofi (SNY) stock is $61.41.
